Coronary Artery Disease Clinical Trial
— CIOfficial title:
Phase I Study to See if a of A Combination Stem Cell Therapy is Safe and Feasible for the Treatment of Severe Coronary Ischemia
Verified date | December 2008 |
Source | TCA Cellular Therapy |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this research study is to determine if the infusion of a combination of stem
cells obtained from the bone marrow of the same patient will contribute to the formation of
new blood vessels in patients with symptomatic severe coronary ischemia. In this trial we
will study the safe use of this therapy and its effects on making new blood vessels will be
evaluated.
Coronary ischemia is intractable angina due to severe coronary artery disease which can
seriously decrease blood flow to the heart.
CI needs a comprehensive treatment since the condition will not improve on its own. The
overall goal of the treatment is to increase blood flow to the heart and improve symptoms of
angina.
The study hypothesis is based on the concept that the process of formation of new blood
vessels is complex and requires the participation of several types of stem cells and growth
factors. The lack of any of these components will produce vessels which are immature and
unable to provide appropriate blood supply to the heart.
Patients eligible to participate in this study are those suffering from severe blockages to
the vessels of the heart and are not candidates for percutaneous revascularization or
surgical procedures.
Once the final mixture of stem cells is prepared, the cells will be intracoronary infused
through a catheter into the blocked vessel of the heart.
Studies will be performed to evaluate if the intracoronary infusion of stem cells is safe,
feasible and works.
Patients will be evaluated for 6 months after cell transplant.
Status | Completed |
Enrollment | 10 |
Est. completion date | February 2009 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Male or Female age 18-20 - Angina Pectoris: CCS Class II or IV or angina symptom equivalent - 70% blockage in at least one epicardial vessel documented within 6 months - Stable medical therapy - Reversible perfusion defects by SPECT - Not a candidate for percutaneous intervention or coronary by-pass surgery Exclusion Criteria: - Previous angiogenic therapy or myocardial laser therapy - Severe valvular heart disease - Recent malignancy or radiation therapy within 6 months - Renal insufficiency with creatinine greater that 2.7 - White blood count greater than 13,000 or lower than 3,000 - Platelet count lower than 60,000 or higher that 500,000 - Pregnant or planning to become pregnant - History of skeletal muscle disease - AST or ALT greater than two times upper limit of normal |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | TCA Cellular Therapy, LLC | Covington | Louisiana |
Lead Sponsor | Collaborator |
---|---|
TCA Cellular Therapy |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety as measured by laboratory assessments, ecg, temperature and holter monitor | 2 weeks | Yes | |
Secondary | Efficacy as measured by SPECT scan and 2-D Echo | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |